Abattis Bioceuticals Corp.
ATTBF
$0.00
$0.000.00%
| 09/30/2019 | 06/30/2019 | 03/31/2019 | 12/31/2018 | 09/30/2018 | |
|---|---|---|---|---|---|
| Net Income | -686.90K | -550.00K | -107.20K | -950.50K | -41.47M |
| Total Depreciation and Amortization | 35.10K | 15.90K | 15.90K | 15.30K | -1.45M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.74M | -1.80K | -659.60K | -125.50K | 42.01M |
| Change in Net Operating Assets | -111.40K | 6.14M | 307.30K | -21.70K | -208.70K |
| Cash from Operations | 2.98M | 5.61M | -443.60K | -1.08M | -1.12M |
| Capital Expenditure | -27.70K | -1.20K | -13.10K | -4.00K | -27.30K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 7.46M | -7.36M | -- | -- | -2.00K |
| Divestitures | -- | -- | -- | -- | 1.53M |
| Other Investing Activities | -10.92M | 1.03M | 1.23M | -37.80K | -1.91M |
| Cash from Investing | -3.49M | -6.33M | 1.22M | -41.80K | -404.30K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 0.00 | 0.00 | 60.00K | 482.30K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 0.00 | 0.00 | 45.40K | 369.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | 0.00 | -- | -- | -- | 0.00 |
| Net Change in Cash | -507.80K | -729.20K | 772.50K | -1.08M | -1.16M |
